Close Menu

Danaher

Upon completion of the deal, Danaher will split into two publicly traded firms, with the life sciences and diagnostics business contained in the company that will retain the Danaher name.

The company lowered its full-year 2015 adjusted EPS estimate on anticipated tougher currency effects.

Core revenues at Beckman Coulter and AB Sciex grew in the mid-single digits during the fourth quarter, CEO Thomas Joyce noted.

Golden Gate Bridge

Officials from Thermo Fisher Scientific, Affymetrix, Danaher, Hologic, Genmark, and Accelerate Diagnostics provided strategic updates at the conference.

Mass spec instrumentation showed solid growth in Q3, with particular strength in academic and government markets.

The story has been updated to include comments from Danaher's third quarter conference call this morning.

Danaher said this week that it has appointed Thomas Joyce as president and CEO and member of the board of directors. He replaces Lawrence Culp, who will transition to a senior advisory role with the company.

NEW YORK (GenomeWeb) – With the launch last year of two US Food and Drug Administration-cleared mass spec microbiology platforms, microbe identification has emerged as one of clinical proteomics' most prominent success stories.

NEW YORK (GenomeWeb) – Danaher today reported that its revenues for the second quarter increased 5 percent year over year, narrowly missing the consensus analyst estimate on the top line but topping expectations on the bottom line.

NEW YORK (GenomeWeb News) – With first quarter results in for major life science mass spec vendors, a mixed picture has emerged as academic, government, and pharma spending delays, particularly in the US and China, countered stronger performance in European markets.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.